ORIGINAL ARTICLE

INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACEUTICAL SCIENCES

Published by JK Welfare & Pharmascope Foundation Journal Home Page: https://ijrps.com

Regulatory Comparative Quality Systems of India and USA and its Significance in Pharmaceutical Industry Facilities

Prabhakar V S, Beula Evangeline C, Aravindhanathan V, Sruthi N, Gowthamarajan K*

Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India

Article History:

Received on: 12 Nov 2020
Revised on: 12 Dec 2020
Accepted on: 14 Dec 2020

Keywords:

Schedule M of D and C Act,
United States FDA,
Good Manufacturing Practice,
Site Master file,
Inspection & Compliance

ABSTRACT

The intentions of the current study are to compare the regulatory requirements of USFDA and CDSCO-Schedule M in GMP with significance to the pharmaceutical industry to speed up the criteria for enforcement to facilitate the regulatory approval of specified pharmaceutical products in the United States and India. The literature search is done using different resources, such as regulatory authority websites, pharmaceutical review articles, journals and public domains. To discuss the numerous dilemmas, root causes and challenges confront by pharmaceutical companies and to suggest remedial and pro-active measures to GMP issues and all pharmaceutical manufacturers are required to develop and enforce effective quality control systems in order to ensure quality. Whereas the regulated markets like the United States have well-established guidance compared to emerging markets like India on good manufacturing practice compliance, to assess the effectiveness of this quality management systems, inspections are carried out on manufacturing units. The primary objective of the analysis is to differentiate between the type of application or license that causes the inspection and the outcome of the inspection and to also provide enough details identified by the authority during the evaluation.

*Corresponding Author

Name: Gowthamarajan K
Phone: +91 94430 89812
Email: gowthamsang@jssuni.edu.in

ISSN: 0975-7538

DOI: https://doi.org/10.26452/ijrps.v11iSPL4.4498

Production and Hosted by

IJRPS | https://ijrps.com

INTRODUCTION

GMP guidelines are not directive guidelines for how goods should be made. There are a set of general principles that have to be followed during development. When a business develops its quality programme and production process, there can be several ways in which it can satisfy GMP requirements. The most productive quality requirements are the responsibility of the organisation to decide. Regulations for the manufacture of pharmaceutical products are rather strict, so the similarities and discrepancies between the GMP specifications for the manufacture of pharmaceutical products and the general requirements used in the manufacture of pharmaceutical products by the regulated countries must be recognized, which will help the pharmaceutical companies of both ROW countries and the regulated countries. (Tga/Pics, 2018). GMP "is that aspect of quality assurance that assures that goods are consistently manufactured and regulated in compliance with quality standards suitable for their intended use and as needed by a marketing authorisation" (Barton, 2007; World Health Organization, 2011; Harper *et al.*, 2007) Both the chosen guidelines define the necessity of equipment and infrastructure under the various editions is represented

Table 1: Comparative study of GMP guideline of Schedule Mand US FDA on Site Master File

S.No	Schedule M	USFDA
1	General information	General information on the manufacture
2	Personnel	Personnel
3	Premises	Premises
4	Documentation	Documentation
5	Production	Production
6	_	Quality management system on the manufacture
7	Quality control	Quality control
8	Distribution, product complaints and recalls	Distribution, product complaints and recalls
9	Self-inspections	Self-inspections
10	Loan license manufacture and licensee	_
11	Sanitation	_
12	Export of drugs	_

Table 2: Comparison of the regulatory requirements for development in the pharmaceutical field

Schedule M	USFDA
Schedule M details the development of PART 1 GMP for premises and materials GMP and requirements of premises Plant and equipment for pharmaceutical products	USFDA outline the manufacturing section in 211-cGMP for finished product e-CFR Title 21 Chapter I Subchapter C PART 21 SUBCHAPTER F- Production and process control.
3. Area of production 3.1. The area of development is designed to enable the production, ideally in uni-flow also with a logical number of operations. 3.2. Separate dedicated and self-contained manufacturing facilities for a critical medicinal drug such as pencilline or live micro-organism biological preparation, shall be made available to order to prevent the possible cross-contamination. 3.3. Working and in-process space shall be sufficient to allow orderly, and placement of equipment and material ad movement of staff to prevent cross-contamination and risk of any manufacturing or wrongly applied. 3.4. Piping, electrical connection and air leakage and common services line are planned, fixed and built for the avoidance purpose. * Part 1 – Schedule M (2019) ** Part 211— USFDA (2016)	Production and process control 211.100: Written procedure; deviation 211.101: Charge in of compound 211.103: Calculation of yield 211.105: Equipment of identification 211.110: Sampling and testing of in-process material and drug product 211.113: Control of microbiological contamination 211.115: Reprocessing

in Table 1.

Comparative Analysis of Development of Regulatory Guidance in Pharmaceutical Industry

Good production practices for facilities and resources Good production practices and specifications are defined in Schedule M for facilities, crops and appliances for medical drugs in PART 1-3. Manufacturing field. Table 2

Existing Good Finished Pharmaceuticals Manufacturing Practice-CFR Title 21 Chapter I Subchapter C Part 211 Subpart F Part 211 Subpart F - Development and Process Management Subchapter C Part 211 Subpart F.

DISCUSSION

Centered on the aforementioned comparative analysis of pharmaceutical industry production controls in compliance with Schedule M of the D and C Act and the USFDA. Good Manufacturing practises recommendations below are the discussion outcomes. For better comprehension purposes, a discussion is conducted under various headings. (Part 1 – Schedule M, 2019; Part 211— USFDA, 2016)

Guidelines Chapters

Schedule M: Schedule M explains the development of good manufacturing practises for facilities and products for good manufacturing practices and specifications for premises, plants and instruments for drug materials in PART 1

USFDA: United States Food & Drug Administration summarizes the production of e-CFR Title 21Chapter I Subchapter C Part 211 Subpart F- Final Products cGMP e-CFR Part 211 Subpart F- Development and control systems

Principle

'In the pharmaceutical industry, development and processing control operate on the theory that' production activities must pursue strictly defined procedures; they must comply with the requirements of Good Industrial Practice in order to produce products of acceptable quality and compliance with the required industrial and marketing authorisations.'

Features of Production Area and Building

The manufacturing process is intended to allow development, ideally in uni-low format through with a specific sequence of operation. Piping, electrical wiring, outlets for air circulation and related lines of service are designed, fixed and installed for avoidance. Service lines are ideally defined by colors and are marked/indicated by the design of the provision and route of the flow. This requirement is defined in Schedule M of the D and C Act as 3.1 and 3.4.

Area of development and characteristics of layout specifications are not protected under Subpart F-USFDA formulation and manufacturing management, but the same is protected under design and facilities under Subpart C.

Access to production area

Details of access to the production area are given in all the selected guidelines Accessible to the processing plant is restricted, as according to the protocols, and only approved staff have a connection to it. Over relevant literature of the Law, this requirement is specified in Schedule M of the D and C Act.

This provision is defined by the USFDA under 211.28(c) of the USFDA, and this section is protected by the pharmaceutical industry personnel provision.

Written procedures; deviations

All production-related activities shall be described in accordance with written procedures, and the requirement of written procedures shall be described in accordance with the various provisions of the preferred guidelines, as follows:

Clause for statutory regulations pursuant to Chapter 3 is not detailed in Schedule M of the Drugs and Cosmetics Act. However, under the various chapters of the Act, this provision is detailed in the production field.

This requirement is described by USFDA in 211.100 written procedures; deviations.

Equipment

The requirement for equipment for the manufacture of drug products is defined in all the selected guidelines. In order to meet the specifications of the product, the equipment must be installed in such a way, a qualified and managed way that all equipment should be properly washed, inspected and confirmed in order to prevent the risk of contamination prior to the commencement of production processes. The unit shall be duly marked for its purpose, the status of its configuration, the content, the date and the sign of the marked personnel. (MHRA, 2020; EU GMP guide part II, 2006; Part 1 – Schedule M, 2019)

Starting and packing materials

Detailed specifications for raw resources or starting materials are set out in the various chapters of the selected guidelines, but this provision is not defined in all the selected guidelines for production and process control, as described in Chapter 10 of Schedule M of the D and C Act. The requirement for starting materials under 211.101 Charge-in components

is described by the USFDA. (MHRA, 2020; Part 1 – Schedule M, 2019).

Weighing and measurement

In accordance with the guidelines chosen for review, all substances used in the manufacture of pharmaceutical components should be specific, measured before being paid for manufacture, all device and instruments for measuring, weighing, monitoring and control should be maintained and modified at pre-specified durations, and documentation should be kept. The equipment needs to be tested regularly or before use, to conduct analytical tests to ensure adequate functioning. (MHRA, 2020; Part 1 – Schedule M, 2019)

Prevention of cross-contamination

Cross-contamination avoidance by appropriate means is described in the GMP guidelines selected for the study. In different sections, as described below, all the guidelines emphasize the subject:

This requirement is defined in Schedule M of the D and C Act as 3.2.

Details of the USFDA guidelines on the prevention of microbial contamination under the 211.113 Microbiological contamination control. (MHRA, 2020; Part 1 – Schedule M, 2019)

In-process testing

The requirement for checking in-processes to ensure that the commodity conforms to predefined demands is defined in all the guidelines selected for analysis. This requirement is defined by the USFDA in 211.110: Sampling and testing of in-process materials and drug products. This is described in Schedule M of the D and C Act under the 22.4 test. (MHRA, 2020; Part 1 – Schedule M, 2019)

Calculation of yield

Yield calculation is important to understand the loss during growth and to take measures to minimise the loss. The measurement of yield is given under USFDA 211.103, which is specified under Section 12.1 documentary evidence in Schedule M of D and C Act, but Schedule M may not specify this specification undergrowth. (MHRA, 2020; Part 1 – Schedule M, 2019)

Packing operations

The packaging labelling and storage under various groups of dosage forms are defined in Schedule M of the D and C Act in the USFDA Act detailing the packaging operations under the packing and labelling control of subpart G. (Part 1 – Schedule M, 2019; Part 211— USFDA, 2016)

RESULTS

Production theory and process control improvement in the pharmaceutical sector

The theory developed, which is standard for all legislative compliance, is based on the above analytical analysis and discussion on production and inventory control in the drug companies, as per the various regulatory guidelines below. The requirements of all the regulatory guidelines with regard to production and process control are satisfactory, following the common principle below. (Singh *et al.*, 2005; Haleem *et al.*, 2015; Tga/Pics, 2018)

Production Area

The production process is engineered to facilitate development, ideally in uni-flow but with a sequential number of steps. Piping, electrical fittings, air conditioning areas and related service lines must be designed, repaired and mounted to avoid the risk of contamination. Preferably, service lines are identified by colours and are labelled/implied by the design of the flow supply and direction. (Harper *et al.*, 2007)

Written procedure

In order to ensure that drug products have the identity, authority, consistency and purity they claim to possess or are represented to possess, written development and process management protocols are in force. These written guidelines shall be conducted, revised and adopted, including any modifications, by the effective organisational units, and shall be reviewed and approved by the quality department.

Equipment

The equipment that has been used for drug development drugs must be of the good quality and size required. Instruments must be constructed in such a way as to be user-friendly, healthy and easy to clean, and should not have an adverse impact on the product. Construction materials do not impact a products consistency.

Both Containers for compound growth and processing, production lines and major equipment used in the manufacture of a batch of a medicinal product shall be clearly marked at all times in order to show its contents and, if appropriate, the production step of the batch. (Harper *et al.*, 2007)

Starting and packing materials

The procurement of starting materials is an essential activity that should require employees with a specific and detailed understanding of producers and distributors. It is only necessary to buy start-

ing materials primarily from the producer of the approved supplier referred to in the relevant specification and, if required, from the developer. Labels must carry at least the further following records: the batch number provided at the time of receipt; the status of the contents, if applicable (e.g. in quarantine, on a test, published, rejected); an expiry date or a date after which re-testing is required, if applicable. (Harper *et al.*, 2007)

Packaging Materials

A similar consideration is paid to the procurement, ability to handle and production control for basic and stamped packaging with regard to the purchase, handling and control of starting materials.

Printed products should be given special consideration. They should be stored under conditions that are sufficiently secure, such as the absence of unauthorised access. A specific reference number or identification mark should be applied to So every distribution of printed or primary product packaging or group of it. (World Health Organization, 2011)

Weighing and measurement

Equipment and instruments for measuring, weighing, recording, and controlling at pre-specified intervals, it should be serviced and adjusted, and documents maintained. Instruments should be tested regularly or prior to use to conduct tests for analytics to ensure adequate functioning. Components for drug product production shall be weighed, calculated, or subdivided as necessary. If an item is removed from the original container to another container, the following details will be used to define the new container:

Name of the component or item code; receipt or control number; new container weight or measurement; lot over which the item was distributed, along with the product, intensity and lot number of the component. The containers are identified correctly. Each of the components is either applied by one person to the batch or checked by a second person. (World Health Organization, 2011)

Cross Contamination Prevention and Microbial Contamination

It is necessary to avoid contamination of a starting material or of a product by another material or product. This possibility of unintentional cross-contamination occurs from the unregulated release from materials and Dust, gases, particles, vapors, sprays or organisms, from equipment residues. It was analysed from intruding pests, and from the clothes, skin, etc. of workers. The value of this risk varies with the type of contaminant and the substance's toxicity. It is important to prevent cross-contamination by taking appropriate technological or organisational steps, such as:

1. Wearing protective equipment as it is handled by goods or materials;
2. Use procedures with proven efficacy for cleaning and decontamination;
3. Cross-contamination prevention measures and their efficacy should be regularly tested according to SOPs.
4. Regular intervals ambience testing should be conducted in the processing areas where susceptible goods are processed. (World Health Organization, 2011)

In-process products and measuring and screening of dosage forms

Written protocols detailing the in-process controls and tests or inspections to be carried out on suitable samples of the in-process materials of each batch shall be identified and followed to ensure batch uniformity and integrity of drug products. Where relevant, such control activities might include but must not be limited to the following:

1. Weight variation of the tablet or capsule; time of disintegration; time and rate of dissolution; solutions' clarity, completeness, or pH.
2. Bioburden research.
3. Identification, power, durability, and sanctity shall be inspected for in-process products, as relevant. (Harper *et al.*, 2007)

Operations of Manufacturing

Before any manufacturing procedure is started, measures need to be taken to verify that all raw material, goods, material contaminants, labelling or documentation not needed for the existing method are sterile and transparent in the working environment and facilities. Once the fault has been rectified, faulty equipment should be removed from service.

After usage, manufacturing equipment should be washed without delay in compliance with comprehensive has written protocols and stored in a separate location or in a way that avoids contamination under clean and dry conditions. (World Health Organization, 2011)

Calculation of yield

Real yields and theoretical yield percentages shall be calculated at the end of each acceptable step of

the drug product's manufacture, processing, packaging or holding. These observations must be performed out by one individual and independently verified by a second individual. (Harper *et al.*, 2007)

Packing operations

Special attention should be given to minimising the risk of cross-contamination, combining or substitution during the development of a packaging operations scheme. Before the start of packaging operations, Measures need to be taken to make sure that the laboratory, packaging rows, printing presses and other services are supplied with are clean and clear of all previously used items, materials or documents, unless they are appropriate for the current operation.

At each packaging platform or section, the title and lot numbering of the material being transported should be shown. Before being filled, the filling containers should be clean. (Harper *et al.*, 2007)

Finished Products

Under conditions set by the producer, finished goods should be kept in quarantine until their final release. It is important to carry out the assessment of finished products and the documentation that is important before the product is available for sale. After publication, under conditions defined by the producer, finished products should be maintained as a functional stock. (World Health Organization, 2011)

CONCLUSIONS

From the above comparative analysis of the selected GMP Guidelines, we conclude that the following points must be taken into account as a standard forum for the preparation of a single site master file. Schedule M and USFDA detailed information of the manufacturer's quality management system are under various headings.

However, Schedule M and USFDA provide the specifics of the manufacturer's quality control system in the general information section. Good manufacturing practice (GMP) is a practice of manufacturing and testing that helps to ensure the quality of the inbuilt product.

ACKNOWLEDGEMENT

The authors would like to thank Department of Science and Technology- fund for the improvement of science and technology infrastructure in Universities and Higher Educational Institutions (DST- FIST), New Delhi for their infrastructure support to our department.

Conflict of Interest

The authors declare that they have no conflict of interest for this study.

Funding Support

The authors declare that they have no funding support for this study.

REFERENCES

Barton, P. 2007. The Great Quinine Fraud": Legality Issues in the "Non-Narcotic" Drug Trade in British India. *The Social History of Alcohol and Drugs*, 22(1):6–25.

EU GMP guide part II 2006. Guidance on Good Manufacturing Practice (GMP)-Production. Human regulatory. European Medicines Agency. [Accessed on 15 July 2006].

Haleem, R. M., *et al.* 2015. Quality in the pharmaceutical industry – A literature review. *Saudi Pharmaceutical Journal*, 23(5):463–469.

Harper, I., *et al.* 2007. Good Manufacturing Practice in the Pharmaceutical Industry–Working Paper 3, prepared for Workshop on 'Tracing Pharmaceuticals in South Asia', 2–3 July. The University of Edinburgh. Pages: 02-35.

MHRA 2020. MHRA Guidance for Specials manufacturers. Medicines and Healthcare Products Regulatory Agency. Pages: 41. [Accessed on 15 January 2015].

Part 1 – Schedule M 2019. Good Manufacturing Practices for Premises and Materials of Good Manufacturing Practices and Requirements of Premises. Plant and Equipment for Pharmaceutical Products. [Accessed on February 2019].

Part 211— USFDA 2016. Current Good Manufacturing Practice for Finished Pharmaceuticals -e-CFR data is current as of January 12, 2016. [Accessed on 21 September 2020].

Singh, S. H., *et al.* 2005. Government of India ministry of health and family welfare department of health and family welfare Lok sabha unstarred question no. 655.

Tga/Pics 2018. Describes about the Production in guide to good manufacturing Practice for medicinal products. Part I. Chapter 5 – Production. Pages: 54. [Accessed On 1 July 2018].

World Health Organization 2011. Annex 3-WHO Good Manufacturing Practices for Pharmaceutical Products: Main Principles, Personnel; Training; Personnel Hygiene. *WHO Expert Committee on Specifications for Pharmaceutical Preparations*, 961:114–119.